Optical advances in skeletal imaging applied to bone metastases

Bone

Volumn 48, Issue 1, 2011, Pages 106-114

  Snoeks, T J A ^a   Khmelinskii, A ^a   Lelieveldt, B P F ^a   Kaijzel, E L ^a   Lowik C W G M ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Endocrinology ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; BIOLUMINESCENCE; BONE METASTASIS; BONE RADIOGRAPHY; CANCER RESEARCH; DIAGNOSTIC IMAGING; FLUORESCENCE IMAGING; HUMAN; IMAGING SYSTEM; INFLAMMATION; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; BONE NEOPLASMS; DIAGNOSTIC IMAGING; FORECASTING; OPTICS AND PHOTONICS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; X-RAY MICROTOMOGRAPHY; X-RAYS;

EID: 78650309923     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.07.027     Document Type: Review

References (105)

1. Pupin M.I. Rontgen rays. Science 1896, 3:231-235.
2. Rontgen W.C. On a new kind of rays. Science 1896, 3:227-231.
3. Goodspeed A.W. Experiments on the rontgen x-rays. Science 1896, 3:236-237.
4. Ambrose J., Hounsfield G. Computerized transverse axial tomography. Br J Radiol 1973, 46:148-149.
5. Hounsfield G.N. Computerized transverse axial scanning (tomography). 1. Description of system. Br J Radiol 1973, 46:1016-1022.
6. Dothager R.S., Flentie K., Moss B., Pan M.H., Kesarwala A., Piwnica-Worms D. Advances in bioluminescence imaging of live animal models. Curr Opin Biotechnol 2009, 20:45-53.
7. Edinger M., Hoffmann P., Contag C.H., Negrin R.S. Evaluation of effector cell fate and function by in vivo bioluminescence imaging. Methods 2003, 31:172-179.
8. Hoffman R.M. The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer 2005, 5:796-806.
9. Kwon H., Enomoto T., Shimogawara M., Yasuda K., Nakajima Y., Ohmiya Y. Bioluminescence imaging of dual gene expression at the single-cell level. Biotechniques 2010, 48:460-462.
10. Michelini E., Cevenini L., Mezzanotte L., Ablamsky D., Southworth T., Branchini B.R., et al. Combining intracellular and secreted bioluminescent reporter proteins for multicolor cell-based assays. Photochem Photobiol Sci 2008, 7:212-217.
11. Michelini E., Cevenini L., Mezzanotte L., Ablamsky D., Southworth T., Branchini B., et al. Spectral-resolved gene technology for multiplexed bioluminescence and high-content screening. Anal Chem 2008, 80:260-267.
12. Mezzanotte L, Kaijzel EL, Michelini E, Que I, Carlotti F, Hoeben R, et al., Spectral unmixing of red and green luciferases for in vivo bioluminescence imaging. European Molecular Imaging Meeting-EMIM 2010, Warsaw, Poland. 27-5-2010.Ref Type: Abstract.
13. Bhaumik S., Gambhir S.S. Optical imaging of Renilla luciferase reporter gene expression in living mice. Proc Natl Acad Sci USA 2002, 99:377-382.
14. Hastings J.W. Chemistries and colors of bioluminescent reactions: a review. Gene 1996, 173:5-11.
15. Pichler A., Prior J.L., Piwnica-Worms D. Imaging reversal of multidrug resistance in living mice with bioluminescence: MDR1 P-glycoprotein transports coelenterazine. Proc Natl Acad Sci USA 2004, 101:1702-1707.
16. Tannous B.A., Kim D.E., Fernandez J.L., Weissleder R., Breakefield X.O. Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol Ther 2005, 11:435-443.
17. Chung E., Yamashita H., Au P., Tannous B.A., Fukumura D., Jain R.K. Secreted Gaussia luciferase as a biomarker for monitoring tumor progression and treatment response of systemic metastases. PLoS ONE 2009, 4:e8316.
18. Minn A.J., Kang Y., Serganova I., Gupta G.P., Giri D.D., Doubrovin M., et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 2005, 115:44-55.
19. Demas J.N., Crosby G.A. Measurement of photoluminescence quantum yields. A review. J Phys Chem 1971, 75:991-1024.
20. Weissleder R., Ntziachristos V. Shedding light onto live molecular targets. Nat Med 2003, 9:123-128.
21. Lim Y.T., Kim S., Nakayama A., Stott N.E., Bawendi M.G., Frangioni J.V. Selection of quantum dot wavelengths for biomedical assays and imaging. Mol Imaging 2003, 2:50-64.
22. Giepmans B.N., Adams S.R., Ellisman M.H., Tsien R.Y. The fluorescent toolbox for assessing protein location and function. Science 2006, 312:217-224.
23. Shcherbo D., Merzlyak E.M., Chepurnykh T.V., Fradkov A.F., Ermakova G.V., Solovieva E.A., et al. Bright far-red fluorescent protein for whole-body imaging. Nat Methods 2007, 4:741-746.
24. Taroni P., Pifferi A., Torricelli A., Comelli D., Cubeddu R. In vivo absorption and scattering spectroscopy of biological tissues. Photochem Photobiol Sci 2003, 2:124-129.
25. Shaner N.C., Campbell R.E., Steinbach P.A., Giepmans B.N., Palmer A.E., Tsien R.Y. Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol 2004, 22:1567-1572.
26. Wang L., Jackson W.C., Steinbach P.A., Tsien R.Y. Evolution of new nonantibody proteins via iterative somatic hypermutation. Proc Natl Acad Sci USA 2004, 101:16745-16749.
27. Shu X., Royant A., Lin M.Z., Aguilera T.A., Lev-Ram V., Steinbach P.A., et al. Mammalian expression of infrared fluorescent proteins engineered from a bacterial phytochrome. Science 2009, 324:804-807.
28. Weissleder R., Tung C.H., Mahmood U., Bogdanov A. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol 1999, 17:375-378.
29. Rogers K.L., Picaud S., Roncali E., Boisgard R., Colasante C., Stinnakre J., et al. Non-invasive in vivo imaging of calcium signaling in mice. PLoS ONE 2007, 2:e974.
30. Roncali E., Savinaud M., Levrey O., Rogers K.L., Maitrejean S., Tavitian B. New device for real-time bioluminescence imaging in moving rodents. J Biomed Opt 2008, 13:054035.
31. Virostko J., Jansen E.D. Validation of bioluminescent imaging techniques. Methods Mol Biol 2009, 574:15-23.
32. Qin C., Yang X., Feng J., Liu K., Liu J., Yan G., et al. Adaptive improved element free Galerkin method for quasi- or multi-spectral bioluminescence tomography. Opt Express 2009, 17:21925-21934.
33. Zhang Q., Yin L., Tan Y., Yuan Z., Jiang H. Quantitative bioluminescence tomography guided by diffuse optical tomography. Opt Express 2008, 16:1481-1486.
34. Leblond F., Davis S.C., Valdes P.A., Pogue B.W. Pre-clinical whole-body fluorescence imaging: review of instruments, methods and applications. J Photochem Photobiol B 2010, 98:77-94.
35. Nahrendorf M., Keliher E., Marinelli B., Waterman P., Feruglio P.F., Fexon L., et al. Hybrid PET-optical imaging using targeted probes. Proc Natl Acad Sci USA 2010, 107:7910-7915.
36. Mansfield J.R., Gossage K.W., Hoyt C.C., Levenson R.M. Autofluorescence removal, multiplexing, and automated analysis methods for in-vivo fluorescence imaging. J Biomed Opt 2005, 10:41207.
37. Levenson R.M., Lynch D.T., Kobayashi H., Backer J.M., Backer M.V. Multiplexing with multispectral imaging: from mice to microscopy. ILAR J 2008, 49:78-88.
38. Lorusso G., Ruegg C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 2008, 130:1091-1103.
39. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2:584-593.
40. Voorzanger-Rousselot N., Juillet F., Mareau E., Zimmermann J., Kalebic T., Garnero P. Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation. Br J Cancer 2006, 95:506-514.
41. Guise T.A., Chirgwin J.M. Transforming growth factor-beta in osteolytic breast cancer bone metastases. Clin Orthop Relat Res 2003, S32-S38.
42. Lin W.W., Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007, 117:1175-1183.
43. Guise T.A., Mohammad K.S., Clines G., Stebbins E.G., Wong D.H., Higgins L.S., et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006, 12:6213s-6216s.
44. Kozloff K.M., Weissleder R., Mahmood U. Noninvasive optical detection of bone mineral. J Bone Miner Res 2007, 22:1208-1216.
45. Kovar JL, Xu X, Simpson MA, and Olive DM. Effective bone labeling for in vivo NIR noninvasive imaging in nude mice. Joint Molecular Imaging Conference-Sept. 2007, Providence, Rhode Island. 9-9-2007.Ref Type: Abstract.
46. Zaheer A., Lenkinski R.E., Mahmood A., Jones A.G., Cantley L.C., Frangioni J.V. In vivo near-infrared fluorescence imaging of osteoblastic activity. Nat Biotechnol 2001, 19:1148-1154.
47. Kozloff K.M., Volakis L.I., Marini J.C., Caird M.S. Near-infrared fluorescent probe traces bisphosphonate delivery and retention in vivo. J Bone Miner Res 2010.
48. Arguello F., Baggs R.B., Frantz C.N. A murine model of experimental metastasis to bone and bone marrow. Cancer Res 1988, 48:6876-6881.
49. Eccles S.A., Welch D.R. Metastasis: recent discoveries and novel treatment strategies. Lancet 2007, 369:1742-1757.
50. Sharpless N.E., Depinho R.A. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006, 5:741-754.
51. Steeg P.S. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006, 12:895-904.
52. Wetterwald A., van der Pluijm G., Que I., Sijmons B., Buijs J., Karperien M., et al. Optical imaging of cancer metastasis to bone marrow: a mouse model of minimal residual disease. Am J Pathol 2002, 160:1143-1153.
53. Kalikin L.M., Schneider A., Thakur M.A., Fridman Y., Griffin L.B., Dunn R.L., et al. In vivo visualization of metastatic prostate cancer and quantitation of disease progression in immunocompromised mice. Cancer Biol Ther 2003, 2:656-660.
54. Kaijzel E.L., Snoeks T.J., Buijs J.T., van der Pluijm G., Lowik C.W. Multimodal imaging and treatment of bone metastasis. Clin Exp Metastasis 2009, 26:371-379.
55. Caysa H., Jacob R., Muther N., Branchini B., Messerle M., Soling A. A redshifted codon-optimized firefly luciferase is a sensitive reporter for bioluminescence imaging. Photochem Photobiol Sci 2009, 8:52-56.
56. Kim J.B., Urban K., Cochran E., Lee S., Ang A., Rice B., et al. Non-invasive detection of a small number of bioluminescent cancer cells in vivo. PLoS ONE 2010, 5:e9364.
57. van der Pluijm G., Sijmons B., Vloedgraven H., Deckers M., Papapoulos S., Lowik C. Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases. J Bone Miner Res 2001, 16:1077-1091.
58. Kovar J.L., Volcheck W.M., Chen J., Simpson M.A. Purification method directly influences effectiveness of an epidermal growth factor-coupled targeting agent for noninvasive tumor detection in mice. Anal Biochem 2007, 361:47-54.
59. Kovar J.L., Volcheck W., Sevick-Muraca E., Simpson M.A., Olive D.M. Characterization and performance of a near-infrared 2-deoxyglucose optical imaging agent for mouse cancer models. Anal Biochem 2009, 384:254-262.
60. Marshall M.V., Draney D., Sevick-Muraca E.M., Olive D.M. Single-dose intravenous toxicity study of IRDye 800CW in Sprague-Dawley rats. Mol Imaging Biol 2010.
61. Gong H., Kovar J., Little G., Chen H., Olive D.M. In vivo imaging of xenograft tumors using an epidermal growth factor receptor-specific affibody molecule labeled with a near-infrared fluorophore. Neoplasia 2010, 12:139-149.
62. Zhou H., Luby-Phelps K., Mickey B.E., Habib A.A., Mason R.P., Zhao D. Dynamic near-infrared optical imaging of 2-deoxyglucose uptake by intracranial glioma of athymic mice. PLoS ONE 2009, 4:e8051.
63. Derynck R., Akhurst R.J., Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001, 29:117-129.
64. Massague J. TGFbeta in Cancer. Cell 2008, 134:215-230.
65. Yin J.J., Selander K., Chirgwin J.M., Dallas M., Grubbs B.G., Wieser R., et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999, 103:197-206.
66. Deckers M., van Dinther M., Buijs J., Que I., Lowik C., van der Pluijm G., et al. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res 2006, 66:2202-2209.
67. Kang Y., He W., Tulley S., Gupta G.P., Serganova I., Chen C.R., et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA 2005, 102:13909-13914.
68. Serganova I., Moroz E., Vider J., Gogiberidze G., Moroz M., Pillarsetty N., et al. Multimodality imaging of TGFbeta signaling in breast cancer metastases. FASEB J 2009, 23:2662-2672.
69. Teitelbaum S.L. Bone resorption by osteoclasts. Science 2000, 289:1504-1508.
70. Drake F.H., Dodds R.A., James I.E., Connor J.R., Debouck C., Richardson S., et al. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem 1996, 271:12511-12516.
71. Garnero P., Borel O., Byrjalsen I., Ferreras M., Drake F.H., McQueney M.S., et al. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 1998, 273:32347-32352.
72. Lecaille F., Weidauer E., Juliano M.A., Bromme D., Lalmanach G. Probing cathepsin K activity with a selective substrate spanning its active site. Biochem J 2003, 375:307-312.
73. Kozloff K.M., Quinti L., Patntirapong S., Hauschka P.V., Tung C.H., Weissleder R., et al. Non-invasive optical detection of cathepsin K-mediated fluorescence reveals osteoclast activity in vitro and in vivo. Bone 2009, 44:190-198.
74. Bremer C., Tung C.H., Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med 2001, 7:743-748.
75. Kessenbrock K., Plaks V., Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52-67.
76. Deguchi J.O., Aikawa M., Tung C.H., Aikawa E., Kim D.E., Ntziachristos V., et al. Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation 2006, 114:55-62.
77. Kaijzel E.L., van Heijningen P., Wielopolski P., Vermeij M., Koning G., van Cappellen W.A., et al. Multimodality imaging reveals a gradual increase in matrix metalloproteinase activity at aneurysmal lesions in live Fibulin-4 mice. Circ Cardiovasc Imaging 2010, 3:567-577.
78. Ntziachristos V., Tung C.H., Bremer C., Weissleder R. Fluorescence molecular tomography resolves protease activity in vivo. Nat Med 2002, 8:757-760.
79. Kato D., Boatright K.M., Berger A.B., Nazif T., Blum G., Ryan C., et al. Activity-based probes that target diverse cysteine protease families. Nat Chem Biol 2005, 1:33-38.
80. Blum G., Mullins S.R., Keren K., Fonovic M., Jedeszko C., Rice M.J., et al. Dynamic imaging of protease activity with fluorescently quenched activity-based probes. Nat Chem Biol 2005, 1:203-209.
81. Blum G., Weimer R.M., Edgington L.E., Adams W., Bogyo M. Comparative assessment of substrates and activity based probes as tools for non-invasive optical imaging of cysteine protease activity. PLoS ONE 2009, 4:e6374.
82. Blum G., von Degenfeld G., Merchant M.J., Blau H.M., Bogyo M. Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. Nat Chem Biol 2007, 3:668-677.
83. Millauer B., Wizigmann-Voos S., Schnurch H., Martinez R., Moller N.P., Risau W., et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993, 72:835-846.
84. Couffinhal T., Kearney M., Witzenbichler B., Chen D., Murohara T., Losordo D.W., et al. Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and atherosclerotic human arteries. Am J Pathol 1997, 150:1673-1685.
85. Rissanen T.T., Vajanto I., Hiltunen M.O., Rutanen J., Kettunen M.I., Niemi M., et al. Expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 (KDR/Flk-1) in ischemic skeletal muscle and its regeneration. Am J Pathol 2002, 160:1393-1403.
86. Vajkoczy P., Farhadi M., Gaumann A., Heidenreich R., Erber R., Wunder A., et al. Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. J Clin Invest 2002, 109:777-785.
87. Witmer A.N., Dai J., Weich H.A., Vrensen G.F., Schlingemann R.O. Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia. J Histochem Cytochem 2002, 50:767-777.
88. Zhang N., Fang Z., Contag P.R., Purchio A.F., West D.B. Tracking angiogenesis induced by skin wounding and contact hypersensitivity using a Vegfr2-luciferase transgenic mouse. Blood 2004, 103:617-626.
89. Ronicke V., Risau W., Breier G. Characterization of the endothelium-specific murine vascular endothelial growth factor receptor-2 (Flk-1) promoter. Circ Res 1996, 79:277-285.
90. Backer M.V., Patel V., Jehning B.T., Claffey K.P., Backer J.M. Surface immobilization of active vascular endothelial growth factor via a cysteine-containing tag. Biomaterials 2006, 27:5452-5458.
91. Backer M.V., Levashova Z., Levenson R., Blankenberg F.G., Backer J.M. Cysteine-containing fusion tag for site-specific conjugation of therapeutic and imaging agents to targeting proteins. Methods Mol Biol 2008, 494:275-294.
92. Blankenberg F.G., Backer M.V., Levashova Z., Patel V., Backer J.M. In vivo tumor angiogenesis imaging with site-specific labeled (99m)Tc-HYNIC-VEGF. Eur J Nucl Med Mol Imaging 2006, 33:841-848.
93. Levashova Z., Backer M., Backer J.M., Blankenberg F.G. Direct site-specific labeling of the Cys-tag moiety in scVEGF with technetium 99m. Bioconjug Chem 2008, 19:1049-1054.
94. Levashova Z., Backer M., Backer J.M., Blankenberg F.G. Imaging vascular endothelial growth factor (VEGF) receptors in turpentine-induced sterile thigh abscesses with radiolabeled single-chain VEGF. J Nucl Med 2009, 50:2058-2063.
95. Backer M.V., Levashova Z., Patel V., Jehning B.T., Claffey K., Blankenberg F.G., et al. Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nat Med 2007, 13:504-509.
96. Griffioen A.W., Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000, 52:237-268.
97. Brooks P.C., Clark R.A., Cheresh D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994, 264:569-571.
98. Xiong J.P., Stehle T., Zhang R., Joachimiak A., Frech M., Goodman S.L., et al. Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science 2002, 296:151-155.
99. Wu Y., Cai W., Chen X. Near-infrared fluorescence imaging of tumor integrin alpha v beta 3 expression with Cy7-labeled RGD multimers. Mol Imaging Biol 2006, 8:226-236.
100. Cai W., Shin D.W., Chen K., Gheysens O., Cao Q., Wang S.X., et al. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett 2006, 6:669-676.
101. Chen X., Conti P.S., Moats R.A. In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Res 2004, 64:8009-8014.
102. Kaijzel E.L., van der Pluijm G., Lowik C.W. Whole-body optical imaging in animal models to assess cancer development and progression. Clin Cancer Res 2007, 13:3490-3497.
103. Kossodo S., Pickarski M., Lin S.A., Gleason A., Gaspar R., Buono C., et al. Dual in vivo quantification of integrin-targeted and protease-activated agents in cancer using fluorescence molecular tomography (FMT). Mol Imaging Biol 2009.
104. Snoeks T.J., Lowik C.W., Kaijzel E.L. 'In vivo' optical approaches to angiogenesis imaging. Angiogenesis 2010, 13:135-147.
105. Pettaway C.A., Pathak S., Greene G., Ramirez E., Wilson M.R., Killion J.J., et al. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 1996, 2:1627-1636.